Literature DB >> 25114502

Artificial tears potpourri: a literature review.

Majid Moshirfar1, Kasey Pierson2, Kamalani Hanamaikai3, Luis Santiago-Caban1, Valliammai Muthappan1, Samuel F Passi1.   

Abstract

Numerous brands and types of artificial tears are available on the market for the treatment of dysfunctional tear syndrome. Past literature has focused on comparing the components of these products on patient's clinical improvement. The wide array of products on the market presents challenges to both clinicians and patients when trying to choose between available tear replacement therapies. Different formulations affect patients based on etiology and severity of disease. In order to provide an unbiased comparison between available tear replacement therapies, we conducted a literature review of existing studies and National Institutes of Health clinical trials on commercially available, brand name artificial tears. Outcomes evaluated in each study, as well as the percent of patients showing clinical and symptomatic improvement, were analyzed. Fifty-one studies evaluating different brands of artificial tears, and their efficacy were identified. Out of the 51 studies, 18 were comparison studies testing brand name artificial tears directly against each other. Nearly all formulations of artificial tears provided significant benefit to patients with dysfunctional tear syndrome, but some proved superior to others. From the study data, a recommended treatment flowchart was derived.

Entities:  

Keywords:  Blink®; CMC; GenTeal®; HPMC; Lacrisert®; Refresh®; Sjogren’s Syndrome; Soothe®; Systane®; TBUT; artificial tears; dry eye; dysfunctional tear syndrome; lipid layer; liquid polyols; ocular surface inflammatory disease; ophthalmic lubricant; polyvinyl alcohol; tear film; tear osmolarity

Year:  2014        PMID: 25114502      PMCID: PMC4124072          DOI: 10.2147/OPTH.S65263

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


  78 in total

1.  [A new therapy concept for the treatment of dry eye--the usefulness of phospholipid liposomes].

Authors:  S Lee; S Dausch; G Maierhofer; D Dausch
Journal:  Klin Monbl Augenheilkd       Date:  2004-10       Impact factor: 0.700

2.  The economic burden of dry eye: a conceptual framework and preliminary assessment.

Authors:  Prabashni Reddy; Oren Grad; Krithika Rajagopalan
Journal:  Cornea       Date:  2004-11       Impact factor: 2.651

Review 3.  Ophthalmic preservatives: focus on polyquaternium-1.

Authors:  Maurizio Rolando; Julie Y Crider; Malik Y Kahook
Journal:  Expert Opin Drug Deliv       Date:  2011-09-09       Impact factor: 6.648

4.  Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness.

Authors:  Umberto Benelli; Marco Nardi; Chiara Posarelli; Timothy G Albert
Journal:  Cont Lens Anterior Eye       Date:  2010-02-12       Impact factor: 3.077

5.  Comparison of initial treatment response to two enhanced-viscosity artificial tears.

Authors:  Robert J Noecker
Journal:  Eye Contact Lens       Date:  2006-05       Impact factor: 2.018

6.  The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample.

Authors:  Polyxane Mertzanis; Linda Abetz; Krithika Rajagopalan; Derek Espindle; Robin Chalmers; Christopher Snyder; Barbara Caffery; Timothy Edrington; Trefford Simpson; J Daniel Nelson; Carolyn Begley
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

7.  The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study.

Authors:  Avni Murat Avunduk; Mustafa Cihat Avunduk; Emily D Varnell; Herbert E Kaufman
Journal:  Am J Ophthalmol       Date:  2003-10       Impact factor: 5.258

8.  An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops.

Authors:  George W Ousler; Clifford Michaelson; Mike T Christensen
Journal:  Cornea       Date:  2007-09       Impact factor: 2.651

9.  Ocular side effects of accutane therapy.

Authors:  S Lerman
Journal:  Lens Eye Toxic Res       Date:  1992

10.  Treatment of chronic dry eye: focus on cyclosporine.

Authors:  George D Kymionis; Dimitrios I Bouzoukis; Vassilios F Diakonis; Charalambos Siganos
Journal:  Clin Ophthalmol       Date:  2008-12
View more
  21 in total

1.  Optimising tear replacement rheology in canine keratoconjunctivitis sicca.

Authors:  D L Williams
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 2.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

3.  Histopathological changes on the ocular surface of New Zealand white rabbits after instillation of a fixed combination of 0.09 % xanthan gum and 0.1 % chondroitin sulfate.

Authors:  Angélica Y Contreras-Rubio; Leopoldo Baiza-Durán; Oscar Olvera-Montaño; Mónica Miranda-Robles; José Bonilla-García; Arieh Mercado-Sesma
Journal:  Int Ophthalmol       Date:  2016-02-27       Impact factor: 2.031

4.  Optical Quality and Tear Film Analysis Before and After Intranasal Stimulation in Patients with Dry Eye Syndrome.

Authors:  Samuel F Passi; Cassandra C Brooks; Atalie C Thompson; Preeya K Gupta
Journal:  Clin Ophthalmol       Date:  2020-07-13

5.  An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding.

Authors:  Pang Chen; Zin Mar; Anthony Giannetti; Susan Hughes; Justine Gilbert; Fang Zhao
Journal:  Hosp Pharm       Date:  2020-11-25

6.  Pilot Study of a "Large-Eye," Surgically Induced Dry Eye Rabbit Model by Selective Removal of the Harderian, Lacrimal, and Meibomian Glands.

Authors:  Arthur S Polans; Jonathan F McAnulty; Paul O Phelps; Soesiawati R Darjatmoko; Christopher K Burris; Daniel M Albert
Journal:  Ocul Oncol Pathol       Date:  2017-07-19

Review 7.  Over the counter (OTC) artificial tear drops for dry eye syndrome.

Authors:  Andrew D Pucker; Sueko M Ng; Jason J Nichols
Journal:  Cochrane Database Syst Rev       Date:  2016-02-23

8.  A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation.

Authors:  Lina Zhu; Junping Ao; Peiling Li
Journal:  Drug Des Devel Ther       Date:  2015-07-29       Impact factor: 4.162

9.  Hyaluronate Acid-Dependent Protection and Enhanced Corneal Wound Healing against Oxidative Damage in Corneal Epithelial Cells.

Authors:  Jing Zhong; Yuqing Deng; Bishan Tian; Bowen Wang; Yifang Sun; Haixiang Huang; Ling Chen; Shiqi Ling; Jin Yuan
Journal:  J Ophthalmol       Date:  2016-04-14       Impact factor: 1.909

Review 10.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.